$NBY
NovaBay Pharmaceuticals, Inc. Stock $nby

$nby Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000143774921026313 Filed on November 12, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$2.641M	$1.840M	$2.170M
YoY Change	39.88%	-15.21%	34.37%
Cost Of Revenue	$1.214M	$493.0K	$536.0K
YoY Change	49.32%	-8.02%	33.67%
Gross Profit	$1.427M	$1.347M	$1.634M
YoY Change	32.74%	-17.56%	34.6%
Gross Profit Margin	54.03%	73.21%	75.3%
Selling, General & Admin	$4.613M	$3.626M	$3.571M
YoY Change	64.93%	1.54%	24.12%
% of Gross Profit	323.27%	269.19%	218.54%
Research & Development	$8.000K	$10.00K	$125.0K
YoY Change	-80.0%	-92.0%	155.1%
% of Gross Profit	0.56%	0.74%	7.65%
Depreciation & Amortization	$87.00K	$13.00K	$12.00K
YoY Change	690.91%	8.33%	-29.41%
% of Gross Profit	6.1%	0.97%	0.73%
Operating Expenses	$4.621M	$3.636M	$3.696M
YoY Change	63.11%	-1.62%	26.32%
Operating Profit	-$3.194M	-$2.289M	-$2.062M
YoY Change	81.68%	11.01%	20.44%
Interest Expense	$4.615M	$0.00	-$1.588M
YoY Change	57587.5%	-100.0%	-187.69%
% of Operating Profit
Other Income/Expense, Net	-$1.577M	$0.00	$429.0K
YoY Change		-100.0%	-159.67%
Pretax Income	-$156.0K	-$2.289M	-$3.221M
YoY Change	-91.09%	-28.94%	1042.2%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$156.0K	-$2.289M	-$3.221M
YoY Change	-91.11%	-28.94%	1042.2%
Net Earnings / Revenue	-5.91%	-124.4%	-148.43%
Basic Earnings Per Share		-$0.05	-$0.08
Diluted Earnings Per Share	-$3.442K	-$50.96K	-$0.08
COMMON SHARES
Basic Shares Outstanding	44.94M	44.94M	40.04M
Diluted Shares Outstanding			40.07M

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.504M	$9.028M	$13.41M
YoY Change	-37.22%	-32.69%	48.7%
Cash & Equivalents	$7.504M	$9.028M	$13.41M
Short-Term Investments
Other Short-Term Assets	$145.0K	$117.0K	$77.00K
YoY Change	42.16%	51.95%	-72.4%
Inventory	$3.220M	$969.0K	$785.0K
Prepaid Expenses
Receivables	$1.668M	$843.0K	$1.119M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.17M	$11.50M	$16.01M
YoY Change	-7.53%	-28.2%	28.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$193.0K	$96.00K	$76.00K
YoY Change	129.76%	26.32%	-40.63%
Goodwill	$4.528M
YoY Change
Intangibles	$5.200M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$476.0K	$476.0K	$476.0K
YoY Change	0.0%	0.0%	-12.18%
Total Long-Term Assets	$10.81M	$742.0K	$1.070M
YoY Change	985.14%	-30.65%	-49.17%
TOTAL ASSETS
Total Short-Term Assets	$13.17M	$11.50M	$16.01M
Total Long-Term Assets	$10.81M	$742.0K	$1.070M
Total Assets	$23.98M	$12.24M	$17.08M
YoY Change	57.36%	-28.35%	16.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.045M	$1.354M	$796.0K
YoY Change	246.03%	70.1%	58.25%
Accrued Expenses	$2.092M	$1.325M	$1.655M
YoY Change	-1.09%	-19.94%	0.79%
Deferred Revenue	$1.272M	$658.0K	$368.0K
YoY Change	121.22%	78.8%	-19.3%
Short-Term Debt	$105.0K	$0.00	$104.0K
YoY Change		-100.0%	-96.58%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.442M	$2.874M	$3.003M
YoY Change	21.5%	-4.3%	-51.97%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$10.37M	$1.000K	$197.0K
YoY Change	11813.79%	-99.49%	-37.46%
Total Long-Term Liabilities	$10.37M	$1.000K	$197.0K
YoY Change	11813.79%	-99.49%	-37.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.442M	$2.874M	$3.003M
Total Long-Term Liabilities	$10.37M	$1.000K	$197.0K
Total Liabilities	$13.81M	$2.875M	$3.200M
YoY Change	372.84%	-10.16%	-71.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$141.9M	-$141.7M	-$134.3M
YoY Change	4.28%	5.52%	9.79%
Common Stock	$478.0K	$450.0K	$417.0K
YoY Change	14.35%	7.91%	65.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.17M	$9.364M	$13.88M
YoY Change
Total Liabilities & Shareholders Equity	$23.98M	$12.24M	$17.08M
YoY Change	57.36%	-28.35%	16.98%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$156.0K	-$2.289M	-$3.221M
YoY Change	-91.11%	-28.94%	1042.2%
Depreciation, Depletion And Amortization	$87.00K	$13.00K	$12.00K
YoY Change	690.91%	8.33%	-29.41%
Cash From Operating Activities	-$4.318M	-$1.468M	-$1.370M
YoY Change	198.82%	7.15%	-8.67%
INVESTING ACTIVITIES
Capital Expenditures	-$8.000K	-$17.00K	-$5.000K
YoY Change	-61.9%	240.0%
Acquisitions
YoY Change
Other Investing Activities	-$11.99M
YoY Change
Cash From Investing Activities	-$12.00M	-$17.00K	-$5.000K
YoY Change	57047.62%	240.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	14.80M	219.0K	6.013M
YoY Change	295800.0%	-96.36%	-12.24%
NET CHANGE
Cash From Operating Activities	-4.318M	-1.468M	-1.370M
Cash From Investing Activities	-12.00M	-17.00K	-5.000K
Cash From Financing Activities	14.80M	219.0K	6.013M
Net Change In Cash	-1.524M	-1.266M	4.638M
YoY Change	4.31%	-127.3%	-13.34%
FREE CASH FLOW
Cash From Operating Activities	-$4.318M	-$1.468M	-$1.370M
Capital Expenditures	-$8.000K	-$17.00K	-$5.000K
Free Cash Flow	-$4.310M	-$1.451M	-$1.365M
YoY Change	202.67%	6.3%	-9.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q3	nby	Stock Based Compensation Expense Related To Non Employee And Director Stock Options StockBasedCompensationExpenseRelatedToNonEmployeeAndDirectorStockOptions	17000	USD
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44943364
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2021Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	149000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	236000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44943000
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44943000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41782000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41782000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	20000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9028000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11952000	USD
CY2021Q3	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	843000	USD
CY2020Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	1106000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	969000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	608000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	657000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	576000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	11497000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	14242000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	170000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	436000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	96000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	476000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	476000	USD
CY2021Q3	us-gaap	Assets Assets	12239000	USD
CY2020Q4	us-gaap	Assets Assets	15238000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1354000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	302000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1325000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2115000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	195000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	416000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2874000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2833000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	87000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	2875000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	2920000	USD
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	450000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	418000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	150643000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	147963000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141729000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-136063000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	9364000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	12318000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12239000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15238000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1840000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2170000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5780000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8046000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	493000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	536000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1562000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3157000	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	1347000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	1634000	USD
	us-gaap	Gross Profit GrossProfit	4218000	USD
	us-gaap	Gross Profit GrossProfit	4889000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	125000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	249000	USD
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1855000	USD
CY2020Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1692000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5323000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4675000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1771000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1879000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4527000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4633000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	3636000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	3696000	USD
	us-gaap	Operating Expenses OperatingExpenses	9886000	USD
	us-gaap	Operating Expenses OperatingExpenses	9557000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2289000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2062000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5668000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4668000	USD
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-0	USD
CY2020Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1589000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	5224000	USD
CY2021Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2020Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1000	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	3000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	429000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	605000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2289000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3221000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5666000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9284000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2289000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-3221000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5666000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9285000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44921000
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40037000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43100000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32614000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	12318000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-1518000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	130000	USD
CY2021Q1	nby	Stock Based Compensation Expense Related To Non Employee And Director Stock Options StockBasedCompensationExpenseRelatedToNonEmployeeAndDirectorStockOptions	53000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	10983000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1859000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	13000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1776000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	242000	USD
CY2021Q2	nby	Stock Based Compensation Expense Related To Non Employee And Director Stock Options StockBasedCompensationExpenseRelatedToNonEmployeeAndDirectorStockOptions	54000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	11209000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2289000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	220000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	151000	USD
CY2021Q3	nby	Stock Based Compensation Expense Related To Non Employee And Director Stock Options StockBasedCompensationExpenseRelatedToNonEmployeeAndDirectorStockOptions	73000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	9364000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	973000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-1582000	USD
CY2020Q1	nby	Stock Issued In Connection With Exercise Of Warrants Value StockIssuedInConnectionWithExerciseOfWarrantsValue	201000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	45000	USD
CY2020Q1	nby	Stock Based Compensation Expense Related To Non Employee And Director Stock Options StockBasedCompensationExpenseRelatedToNonEmployeeAndDirectorStockOptions	12000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-349000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4482000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5220000	USD
CY2020Q2	nby	Stock Issued In Connection With Exercise Of Warrants Value StockIssuedInConnectionWithExerciseOfWarrantsValue	468000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	92000	USD
CY2020Q2	nby	Stock Based Compensation Expense Related To Non Employee And Director Stock Options StockBasedCompensationExpenseRelatedToNonEmployeeAndDirectorStockOptions	-2000	USD
CY2020Q2	nby	Adjustments To Additional Paid In Capital Stock Option Modification AdjustmentsToAdditionalPaidInCapitalStockOptionModification	36000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	983000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-3221000	USD
CY2020Q3	nby	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	9293000	USD
CY2020Q3	nby	Stock Issued In Connection With Exercise Of Warrants Value StockIssuedInConnectionWithExerciseOfWarrantsValue	6425000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	220000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	142000	USD
CY2020Q3	nby	Adjustments To Additional Paid In Capital Stock Option Modification AdjustmentsToAdditionalPaidInCapitalStockOptionModification	17000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	13882000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5666000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9285000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	40000	USD
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-0	USD
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	54000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-0	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000	USD
	nby	Share Based Compensation Expense For Stock Option Modification ShareBasedCompensationExpenseForStockOptionModification	0	USD
	nby	Share Based Compensation Expense For Stock Option Modification ShareBasedCompensationExpenseForStockOptionModification	53000	USD
	nby	Vesting Of Employee Restricted Stock Awards VestingOfEmployeeRestrictedStockAwards	2000	USD
	nby	Vesting Of Employee Restricted Stock Awards VestingOfEmployeeRestrictedStockAwards	2000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Restricted Stock Expense RestrictedStockExpense	13000	USD
	us-gaap	Restricted Stock Expense RestrictedStockExpense	220000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	5224000	USD
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-0	USD
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	3000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	141000	USD
	nby	Interest Expense Related To Amortization Of Debt Issuance Related To Related Party Notes Payable InterestExpenseRelatedToAmortizationOfDebtIssuanceRelatedToRelatedPartyNotesPayable	0	USD
	nby	Interest Expense Related To Amortization Of Debt Issuance Related To Related Party Notes Payable InterestExpenseRelatedToAmortizationOfDebtIssuanceRelatedToRelatedPartyNotesPayable	2000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-263000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	226000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	361000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	293000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	81000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-191000	USD
	nby	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-266000	USD
	nby	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-734000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	262000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	355000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-307000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-784000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	28000	USD
	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	0	USD
	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	73000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4874000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3276000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-44000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1994000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5220000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7094000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	-0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1563000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	-0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1994000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9757000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2924000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6476000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12427000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7412000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9503000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13888000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	61000	USD
	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	0	USD
	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	9293000	USD
	nby	Related Party Loan Interest Paid Via Accounts Receivable RelatedPartyLoanInterestPaidViaAccountsReceivable	0	USD
	nby	Related Party Loan Interest Paid Via Accounts Receivable RelatedPartyLoanInterestPaidViaAccountsReceivable	173000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include contract liabilities related to product sales, useful lives for property and equipment and related depreciation calculations, assumptions for valuing options and warrants, income taxes and other contingencies. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	100000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	200000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9028000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11952000	USD
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	475000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	475000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9503000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12427000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentrations of Credit Risk and Major Partners</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a highly-rated, major financial institution in the United States. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deposits in this bank <em style="font: inherit;"> may </em>exceed the amount of federal insurance provided on such deposits. The Company does <em style="font: inherit;">not</em> believe it is exposed to significant credit risk due to the financial position of the financial institution in which the deposits are held. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">During the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;">2020,</em> Company revenues were derived primarily from sales of Avenova. During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;">2020,</em> revenues during the <em style="font: inherit;">second</em> quarter of that period were derived primarily from sales of <em style="font: inherit;">KN95</em> Masks in response to the national need for PPE.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">During the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;">2020,</em> revenues from each product were as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine months Ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Avenova</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,763</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,835</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,221</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,509</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">KN95 Masks</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">69</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other products</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">71</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">263</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">540</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total product revenue, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,167</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,761</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,038</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other revenue, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total sales, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,840</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,780</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,046</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;">2020,</em> sales of Avenova via Amazon comprised 55% and 47% of total Avenova net revenue, respectively. During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;">2020,</em> sales of Avenova via Amazon comprised 57% and 46% of total Avenova net revenue, respectively. <em style="font: inherit;">No</em> other individual distributor comprised greater than <em style="font: inherit;">10%</em> of total Avenova net revenue during the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;">2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;"> December 31, 2020, </em>accounts receivable from our major distribution partners greater than <em style="font: inherit;">10%</em> were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 0pt; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%; border-bottom: 1px solid black;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Major distribution partner</b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Avenova Direct via Amazon</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Distributor A</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Distributor B</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Chongqing Pioneer Pharma Holdings Limited</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Distributor C</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Not greater than 10%</b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><b> </b></td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company relies on <em style="font: inherit;">two</em> contract manufacturers to produce its products. The Company does <em style="font: inherit;">not</em> own any manufacturing facilities and intends to continue to rely on <em style="font: inherit;">third</em> parties for the supply of finished goods. Contract manufacturers <em style="font: inherit;"> may </em>or <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be able to meet the Company’s needs with respect to timing, quantity or quality. In particular, it is possible that we <em style="font: inherit;"> may </em>suffer from unexpected supply chain delays in light of the ongoing COVID-<em style="font: inherit;">19</em> pandemic.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1840000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2170000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5780000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8046000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021Q3	us-gaap	Advertising Expense AdvertisingExpense	800000	USD
CY2020Q3	us-gaap	Advertising Expense AdvertisingExpense	500000	USD
	us-gaap	Advertising Expense AdvertisingExpense	2300000	USD
	us-gaap	Advertising Expense AdvertisingExpense	1300000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11029000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10395000
CY2021Q3	nby	Prepaid Inventory PrepaidInventory	214000	USD
CY2020Q4	nby	Prepaid Inventory PrepaidInventory	0	USD
CY2021Q3	us-gaap	Prepaid Insurance PrepaidInsurance	150000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	165000	USD
CY2021Q3	nby	Prepaid Financing Cost Current PrepaidFinancingCostCurrent	104000	USD
CY2020Q4	nby	Prepaid Financing Cost Current PrepaidFinancingCostCurrent	0	USD
CY2021Q3	nby	Prepaid Sales Rebate PrepaidSalesRebate	44000	USD
CY2020Q4	nby	Prepaid Sales Rebate PrepaidSalesRebate	144000	USD
CY2021Q3	nby	Prepaid Due And Subscriptions PrepaidDueAndSubscriptions	18000	USD
CY2020Q4	nby	Prepaid Due And Subscriptions PrepaidDueAndSubscriptions	53000	USD
CY2021Q3	nby	Prepaid Patents PrepaidPatents	10000	USD
CY2020Q4	nby	Prepaid Patents PrepaidPatents	47000	USD
CY2021Q3	nby	Prepaid Security Deposit For Lease PrepaidSecurityDepositForLease	0	USD
CY2020Q4	nby	Prepaid Security Deposit For Lease PrepaidSecurityDepositForLease	65000	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	117000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	102000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	657000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	576000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	730000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	686000	USD
CY2021Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	271000	USD
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	159000	USD
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	847000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	685000	USD
CY2021Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	149000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	236000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	969000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	608000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	634000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	602000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	96000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84000	USD
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13000	USD
CY2020Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	40000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	726000	USD
CY2021Q3	nby	Contract With Customer Accrued Liabilities Current ContractWithCustomerAccruedLiabilitiesCurrent	579000	USD
CY2020Q4	nby	Contract With Customer Accrued Liabilities Current ContractWithCustomerAccruedLiabilitiesCurrent	730000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	396000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	632000	USD
CY2021Q3	nby	Accrued Sublease Security Deposit Current AccruedSubleaseSecurityDepositCurrent	0	USD
CY2020Q4	nby	Accrued Sublease Security Deposit Current AccruedSubleaseSecurityDepositCurrent	198000	USD
CY2021Q3	nby	Accrued Inventory Current AccruedInventoryCurrent	0	USD
CY2020Q4	nby	Accrued Inventory Current AccruedInventoryCurrent	181000	USD
CY2021Q3	nby	Accrued Consulting Service Current AccruedConsultingServiceCurrent	0	USD
CY2020Q4	nby	Accrued Consulting Service Current AccruedConsultingServiceCurrent	98000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	350000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	276000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1325000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2115000	USD
CY2021Q2	us-gaap	Proceeds From Legal Settlements ProceedsFromLegalSettlements	300000	USD
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	99000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	212000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	298000	USD
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	-0	USD
CY2020Q3	us-gaap	Sublease Income SubleaseIncome	105000	USD
	us-gaap	Sublease Income SubleaseIncome	-0	USD
	us-gaap	Sublease Income SubleaseIncome	421000	USD
CY2021Q3	us-gaap	Lease Cost LeaseCost	99000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	107000	USD
	us-gaap	Lease Cost LeaseCost	298000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y6M
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M
	us-gaap	Lease Cost LeaseCost	305000	USD
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	113000	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	236000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	339000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	816000	USD
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1200000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	114000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	88000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	202000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	196000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	195000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	196000	USD
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6800000	USD
CY2020Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	200000	USD
CY2020Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	20000
CY2020Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6000	USD
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7067000
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.63
	nby	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	15000
	nby	Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice	0.67
	nby	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	-0
	nby	Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice	0
	nby	Class Of Warrant Or Right Forfeited During Period ClassOfWarrantOrRightForfeitedDuringPeriod	-0
	nby	Class Of Warrant Or Right Forfeited During Period Weighted Average Exercise Price ClassOfWarrantOrRightForfeitedDuringPeriodWeightedAverageExercisePrice	0
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7082000
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.63
CY2020Q4	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding	3165000
CY2020Q4	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice	2.05
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	189000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	291000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.74
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1228000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	249000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.39
CY2021Q3	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding	3947000
CY2021Q3	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice	1.54
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	633000	USD
CY2021Q3	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingNumber	3601000
CY2021Q3	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.64
	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P7Y4M24D
CY2021Q3	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	562000	USD
CY2021Q3	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriod	1802000
CY2021Q3	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriodWeightedAverageGrantDateFairValue	2.77
	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedWeightedAverageRemainingContractualTerm	P5Y7M6D
CY2021Q3	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAggregateIntrinsicValue	34000	USD
CY2021Q3	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Number ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableNumber	1802000
CY2021Q3	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageExercisePrice	2.77
	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageRemainingContractualTerm	P5Y7M6D
CY2021Q3	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Aggregate Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableAggregateIntrinsicValue	34000	USD
CY2021Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y5M12D
CY2021Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021Q3	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	100000	USD
	us-gaap	Related Party Costs RelatedPartyCosts	90000	USD
CY2020Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	200000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	224000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	176000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	702000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	359000	USD
CY2020Q4	nby	Contract With Customer Liability Deferred Revenue Current ContractWithCustomerLiabilityDeferredRevenueCurrent	2000	USD
	nby	Contract With Customer Liability Deferred Revenue Current Additions ContractWithCustomerLiabilityDeferredRevenueCurrentAdditions	122000	USD
	nby	Contract With Customer Liability Deferred Revenue Current Deductions ContractWithCustomerLiabilityDeferredRevenueCurrentDeductions	2000	USD
CY2021Q3	nby	Contract With Customer Liability Deferred Revenue Current ContractWithCustomerLiabilityDeferredRevenueCurrent	122000	USD
CY2020Q4	nby	Contract With Customer Liability Product Contracts Current ContractWithCustomerLiabilityProductContractsCurrent	573000	USD
	nby	Contract With Customer Liability Product Distribution Current Additions ContractWithCustomerLiabilityProductDistributionCurrentAdditions	1213000	USD
	nby	Contract With Customer Liability Product Distribution Current Deductions ContractWithCustomerLiabilityProductDistributionCurrentDeductions	1250000	USD
CY2021Q3	nby	Contract With Customer Liability Product Contracts Current ContractWithCustomerLiabilityProductContractsCurrent	536000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	575000	USD
	nby	Contract With Customer Liability Current Additions ContractWithCustomerLiabilityCurrentAdditions	1335000	USD
	nby	Contract With Customer Liability Current Deductions ContractWithCustomerLiabilityCurrentDeductions	1252000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	658000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5780000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8046000	USD
CY2021Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	USD
CY2020Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	175000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	173000	USD
CY2021Q3	us-gaap	Related Party Costs RelatedPartyCosts	0	USD
CY2020Q3	us-gaap	Related Party Costs RelatedPartyCosts	0	USD
	us-gaap	Related Party Costs RelatedPartyCosts	131000	USD
CY2021Q3	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	0	USD
CY2020Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	8000	USD
CY2021Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	USD
CY2020Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	160000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	251000	USD

Files In Submission

Name	View Source	Status
0001437749-21-026313-index-headers.html	Edgar Link	pending
0001437749-21-026313-index.html	Edgar Link	pending
0001437749-21-026313.txt	Edgar Link	pending
0001437749-21-026313-xbrl.zip	Edgar Link	pending
ex_303906.htm	Edgar Link	pending
ex_303907.htm	Edgar Link	pending
ex_303908.htm	Edgar Link	pending
ex_303909.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nby-20210930.xsd	Edgar Link	pending
nby-20210930_cal.xml	Edgar Link	unprocessable
nby-20210930_def.xml	Edgar Link	unprocessable
nby-20210930_lab.xml	Edgar Link	unprocessable
nby-20210930_pre.xml	Edgar Link	unprocessable
nby20210930_10q.htm	Edgar Link	pending
nby20210930_10q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NBY
NovaBay Pharmaceuticals, Inc. Stock $nby

2021 Q4 Form 10-Q Financial Statement

#000143774921026313 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBY NovaBay Pharmaceuticals, Inc. Stock $nby

2021 Q4 Form 10-Q Financial Statement

#000143774921026313 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBY
NovaBay Pharmaceuticals, Inc. Stock $nby